Growth inhibition and induction of apoptosis in SGC‑7901 human gastric cancer cells by evodiamine.
Evodiamine is one of the major bioactive compounds isolated and purified from the fruit of Fructus Evodiae. Numerous studies have indicated that evodiamine exhibits activity against human tumor cells. In the present study, the effect of evodiamine on the proliferation and apoptosis of SGC-7901 human gastric cancer cells and the correlative mechanisms were investigated. This may provide further experimental evidence of the pharmacological actions of evodiamine and a strategy for its use as a novel chemotherapeutic drug. Following treatment with evodiamine, the typical morphological changes of apoptosis were observed in human SGC-7901 cells. Cell cycle analysis indicated that evodiamine induced G2/M phase arrest in SGC-7901 cells and flow cytometry revealed that evodiamine induced apoptosis. Analysis of the enzymatic activity demonstrated that evodiamine increased the activity of caspase-3, -8 and -9 in SGC-7901 cells. The protein expression of caspase-3, -8 and -9 and Bax increased, and the expression of Bcl-2 decreased following treatment with evodiamine. These results suggest that evodiamine is able to inhibit the proliferation of SGC-7901 cells by inhibiting the cell cycle at G2/M phase and inducing apoptosis in SGC-7901 cells by activating caspase-3, -8 and -9, and altering the expression of caspase-3, Bax and Bcl-2.